Cargando…

P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol

INTRODUCTION: Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with OSA (37.5–150 mg/day) or narcolepsy (75–150 mg/day). This study examined characteristics of patients with OSA initiating solriamfetol and pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, H, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Thorpy, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109363/ http://dx.doi.org/10.1093/sleepadvances/zpab014.188

Ejemplares similares

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021)

Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario
por: Singh, Haramandeep, et al.
Publicado: (2022)

A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019)

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment
por: Schweitzer, Paula K., et al.
Publicado: (2021)

Solriamfetol for the Use of Narcolepsy: A Systematic Review
por: Iturburu, Alisson, et al.
Publicado: (2022)

Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)

Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation
por: Al-Rifai, Nafisah, et al.
Publicado: (2023)

Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol
por: Krief, Stéphane, et al.
Publicado: (2021)

Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
por: Weaver, Terri E., et al.
Publicado: (2020)

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives
por: Abad, Vivien C
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea
por: Malhotra, Atul, et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
por: Zomorodi, Katie, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
por: Carter, Lawrence P, et al.
Publicado: (2018)

Assessment of obstructive sleep apnoea (OSA) in children: an update
por: SAVINI, S., et al.
Publicado: (2019)

Obstructive sleep apnoea syndrome (OSAS): effects on the vestibular system
por: GALLINA, S., et al.
Publicado: (2010)

Titration-free massively parallel pyrosequencing using trace amounts of starting material
por: Zheng, Zongli, et al.
Publicado: (2010)

Start low, go fast? Antipsychotic titration patterns at an inpatient psychiatric hospital
por: Vadiei, Nina, et al.
Publicado: (2020)

Strength Training for Arthritis Trial (START): design and rationale
por: Messier, Stephen P, et al.
Publicado: (2013)

Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)
por: Pituskin, Edith, et al.
Publicado: (2016)

The Burden of Respiratory Alterations during Sleep on Comorbidities in Obstructive Sleep Apnoea (OSA)
por: Tondo, Pasquale, et al.
Publicado: (2022)

CHINA Continuing coopera tion
Publicado: (1991)

Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes
por: Viciani, Elisa, et al.
Publicado: (2016)

Obstructive sleep apnoea syndrome (OSAS) as a risk factor for secondary osteoporosis in children
por: Sies, Nur Syazwin, et al.
Publicado: (2021)

Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023)

StartLink and StartLink+: Prediction of Gene Starts in Prokaryotic Genomes
por: Gemayel, Karl, et al.
Publicado: (2021)

Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial
por: Masse, Marie-Hélène, et al.
Publicado: (2020)

COLLABORA TION AGREEMENT No. K1257
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2006)

An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
por: de Leon, Jose, et al.
Publicado: (2022)

Patients’ with obstructive sleep apnoea syndrome (OSAS) preferences and demand for treatment: a discrete choice experiment
por: Krucien, Nicolas, et al.
Publicado: (2013)

Circulating Superoxide Dismutase Concentrations in Obstructive Sleep Apnoea (OSA): A Systematic Review and Meta-Analysis
por: Pau, Maria Carmina, et al.
Publicado: (2021)

Obstructive Sleep Apnoea and Lipid Metabolism: The Summary of Evidence and Future Perspectives in the Pathophysiology of OSA-Associated Dyslipidaemia
por: Meszaros, Martina, et al.
Publicado: (2022)

P099 Physiological phenotypes of obstructive sleep apnoea (OSA) in Pacific Islanders and equally obese Caucasians
por: Naidoo, C, et al.
Publicado: (2021)

Starting electronics
por: Brindley, Keith
Publicado: (2005)

Getting started
por: DELL' ACQUA, Andrea
Publicado: (2000)

An impressive start
Publicado: (2011)

It Starts With Clients
por: Sobel, Andrew
Publicado: (2020)

Starting electronics
por: Brindley, Keith
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ei97mmshb4kbd39p7107cc9gpd